The Generics Bulletin Podcast: Stelara Biosimilar Launches In The US

episode

Citeline Podcasts not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

OUR INSANE HOUSE PARTY GONE WRONG! -You Should Know Podcast- 1h 21m · 21 Sep 2026 · You Should Know Podcast

Where is Austin Tice? 1. 'We believe he’s alive' 34 min · 21 Sep 2026 · The Documentary Podcast

Arsenal battered in Brighton as Manchester City go clear: Football Weekly 54 min · 21 Sep 2026 · Football Weekly

NPR News: 09-21-2026 8AM EDT 4 min · 21 Sep 2026 · NPR News Now

The Data Gold Rush_ Who Really Owns Your Digital Footprint 2 min · 21 Sep 2026 · Conspiracy Theories Exploring The Unseen

8AM ET 09/21/2026 Newscast 3 min · 21 Sep 2026 · Fox News Hourly Update

Report any issue

Source

Recorded11 Mar 2025

Publisherfeeds.soundcloud.com ↗

Handlerec:4677288

Show notes

Generics Bulletin editors Dave Wallace and Dean Rudge discuss the latest updates on Stelara (ustekinumab) biosimilars in the US, including recent launches, pricing strategies, and parallels with the biosimilar Humira (adalimumab) experience.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related